DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

The trial will enrol patients with mCRC who are microsatellite stable (MSS), wild type (WT) RAS, WT BRAF, and human epidermal ...

Chemotherapy for three months demonstrates lower side effects, suggesting its use as standard care compared with six months.

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant ...

All medicines have risks and benefits. Your doctor has weighed the risks of you using oxaliplatin against the benefits they expect it will have for you. If you have any concerns about taking this ...

Thirty-five patients did not advance to study treatment after oxaliplatin most commonly due to withdrawing consent (n=15), disease progression (n=7), and other reasons (n=13) (12 in GRANITE arm; 23 in ...

The following is a summary of "Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic ...

Ferroptosis offers new strategies to combat treatment resistance in digestive tract cancers, enhancing the efficacy of ...

We compared the gene expression patterns of oxaliplatin-resistant cell lines with the patterns of their sensitive counterparts in an attempt to discover universal mechanisms that characterize ...

Additionally, other clinical and non-clinical data suggest BXQ-350 has activity in chemotherapy-induced peripheral neuropathy, an area of high unmet medical need in patients treated with oxaliplatin ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...